Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are intolerant to other treatments.
Johnson & Johnson is hoping its new acquisition Actelion will help stave off the effects of a price squeeze in the US, and a cheaper biosimilar of its bestseller, Remicade.
